Menu

Latest Pharma Insights



Ivonescimab CRL Indicates OS Significance, Warning To Other PD-(L)1xVEGF Bispecifics
Missing the co-primary endpoint of overall survival in the Phase III HARMONi trial, Summit/Akeso’s ivonescimab has been rejected by the US FDA for approval in post-EGFR inhibitor non-squamous NSCLC.
Scrip - November 16, 2026
Scrip’s Five Must-Know Things: Rasonque’s Stellar Launch, Biotech Deal Tips, Teva’s Innovation Pivot
In this week's episode: Rasonque’s stellar launch; veterans share partnering wisdom; pessimism over Lp(a) drugs; cell therapy promise at ACR; and Teva’s innovation ambitions.
Scrip - November 16, 2026
IQ Bar Fails NAD Test For Brain, Nutrition Claims
Firm submitted irrelevant evidence to NAD for express claim “Superior brain and body nutrition” after withdrawing numerous similar claims and implied claim that its “IQ Bars are better than competing snack bars by providing noticeable improvements in cognition, physical performance and strength.”
HBW Insight - November 16, 2026

Ivonescimab CRL Indicates OS Significance, Warning To Other PD-(L)1xVEGF Bispecifics
Missing the co-primary endpoint of overall survival in the Phase III HARMONi trial, Summit/Akeso’s ivonescimab has been rejected by the US FDA for approval in post-EGFR inhibitor non-squamous NSCLC.
Scrip - November 16, 2026
Scrip’s Five Must-Know Things: Rasonque’s Stellar Launch, Biotech Deal Tips, Teva’s Innovation Pivot
In this week's episode: Rasonque’s stellar launch; veterans share partnering wisdom; pessimism over Lp(a) drugs; cell therapy promise at ACR; and Teva’s innovation ambitions.
Scrip - November 16, 2026

Tandem’s FDA Clearance Of Tandem Mobi Tubeless Sets Up Competitive Race In 2027, Analysts Say
Tandem received FDA clearance for a tubeless Mobi system expected to be launched in the first half of 2027. Beta Bionics and Medtronic are also expected to launch patch-pumps in 2027.
Medtech Insight - November 13, 2026
Terumo Lowers FY Guidance As RelayPro Recall Scope Widens
Despite record year, aortic product troubles begin to weigh on profits for Japan’s largest medtech firm.
Medtech Insight - November 13, 2026
Medtech Majors Favor Spin-Offs And Tuck-Ins Over Big Buys On Q3 Earnings Calls
Medtech deal value through September has already overtaken all of 2025. Yet on third-quarter calls, the largest companies talked more about separating businesses, finishing integrations and keeping new purchases small than about the next big buy.
Medtech Insight - November 13, 2026
CMS Expands Outpatient Surgery Coverage, Approves Nine Devices in 2027 Hospital Payment Final Rule
CMS's 2027 OPPS final rule expands outpatient procedure coverage, approves nine medical devices for transitional pass-through payments, and establishes a new payment framework for software-based diagnostic services. The rule also revises some imaging reimbursement policies.
Medtech Insight - November 13, 2026

IQ Bar Fails NAD Test For Brain, Nutrition Claims
Firm submitted irrelevant evidence to NAD for express claim “Superior brain and body nutrition” after withdrawing numerous similar claims and implied claim that its “IQ Bars are better than competing snack bars by providing noticeable improvements in cognition, physical performance and strength.”
HBW Insight - November 16, 2026

Gedeon Richter Urges Countries To Recalibrate Biosimilar Tenders, Citing Supply Shortfalls
Gedeon Richter says it will limit how many molecules it develops at once unless European biosimilar pricing stabilizes, as biotech revenue rose 34% in Q3 2026.
Generics Bulletin - November 13, 2026
Sandoz And Lupin Roll Out European Ranibizumab
The launch of the Ranluspec ranibizumab biosimilar to Lucentis fills a gap in Sandoz’s portfolio while giving Lupin access to the European market.
Generics Bulletin - November 13, 2026

Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power
Formulary placement is rented real estate: PBMs keep products that generate prescription demand. Rebates mean little without volume, so pharma should start market access thinking in Phase II, not after filing.
In Vivo - November 13, 2026
Preventive Medicine’s Bottleneck Is Not Science – It’s Economics
Gene therapies that could prevent or cure disease in a single dose are drawing billions in investment, but US and European health systems are built to pay for chronic care over a lifetime. Unless payers rethink incentives for one-time treatment, economics may set the pace more than science.
In Vivo - November 13, 2026